At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DFTX Definium Therapeutics
Not Yet Opened 05-14 16:00:00 EDT
21.35
-0.66
-3.00%
盘后21.05
-0.30-1.41%
19:59 EDT
High22.23Low21.28Vol1.09M
Open22.10D1 Closing22.01Amplitude4.30%
Mkt Cap2.33BTradable Cap2.20BTotal Shares109.00M
T/O23.45MT/O Rate1.06%Tradable Shares103.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Stock Track | Definium Therapeutics Soars 5.15% Intraday After Analyst Reiterates Buy Rating with $70 Price Target on Pipeline Confidence
Stock Track  ·  05-14 01:45
Stock Track | Definium Therapeutics Soars 5.15% Intraday After Analyst Reiterates Buy Rating with $70 Price Target on Pipeline Confidence
Definium Therapeutics: Buy Rating Reiterated with Unchanged $70 Price Target on Robust Late-Stage DT120 Pipeline and De-Risked Phase 3 Programs
TIPRANKS  ·  05-13 18:35
Definium Therapeutics: Buy Rating Reiterated with Unchanged $70 Price Target on Robust Late-Stage DT120 Pipeline and De-Risked Phase 3 Programs
Definium Therapeutics says first patient dosed in Ascend study
TIPRANKS  ·  05-12 20:39
Definium Therapeutics says first patient dosed in Ascend study
BRIEF-Definium Therapeutics Announces First Patient Dosed In Ascend
Reuters  ·  05-12 19:00
BRIEF-Definium Therapeutics Announces First Patient Dosed In Ascend
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 Odt in Major Depressive Disorder
THOMSON REUTERS  ·  05-12 19:00
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 Odt in Major Depressive Disorder
Definium Therapeutics Inc: Topline Data From 12-Week Double-Blind Period Is Anticipated in 2027
THOMSON REUTERS  ·  05-12 19:00
Definium Therapeutics Inc: Topline Data From 12-Week Double-Blind Period Is Anticipated in 2027
Definium Therapeutics grants inducement stock options for 255,340 shares to new hires
Reuters  ·  05-12
Definium Therapeutics grants inducement stock options for 255,340 shares to new hires
Definium Therapeutics Is Maintained at Overweight by Piper Sandler
Dow Jones  ·  05-08
Definium Therapeutics Is Maintained at Overweight by Piper Sandler
Stock Track | Definium Therapeutics Plummets 5.34% Intraday Following Analyst Price Target Reduction
Stock Track  ·  05-08
Stock Track | Definium Therapeutics Plummets 5.34% Intraday Following Analyst Price Target Reduction
RBC Capital Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)
TIPRANKS  ·  05-08
RBC Capital Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)
Definium Therapeutics price target lowered to $48 from $49 at Piper Sandler
TIPRANKS  ·  05-08
Definium Therapeutics price target lowered to $48 from $49 at Piper Sandler
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX)
TIPRANKS  ·  05-08
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX)
Definium Therapeutics releases corporate presentation outlining DT120 ODT Phase 3 program in GAD, MDD
Reuters  ·  05-08
Definium Therapeutics releases corporate presentation outlining DT120 ODT Phase 3 program in GAD, MDD
Definium Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-08
Definium Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Definium Therapeutics Q1 net loss widens on higher R&D costs
Reuters  ·  05-08
Definium Therapeutics Q1 net loss widens on higher R&D costs
Definium Therapeutics Q1 EPS $(0.71) Misses $(0.48) Estimate. Cash And Equivalents Of $373.4M
Benzinga  ·  05-08
Definium Therapeutics Q1 EPS $(0.71) Misses $(0.48) Estimate. Cash And Equivalents Of $373.4M
Definium Q1 FY26 net loss widens to $77.1 million; R&D expense jumps 77.5% to $41.5 million
Reuters  ·  05-08
Definium Q1 FY26 net loss widens to $77.1 million; R&D expense jumps 77.5% to $41.5 million
BRIEF-Definium Therapeutics Inc Q1 Net Income USD -77.098 Million
Reuters  ·  05-08
BRIEF-Definium Therapeutics Inc Q1 Net Income USD -77.098 Million
Definium Therapeutics to report first-quarter results in webcast update
Reuters  ·  05-01
Definium Therapeutics to report first-quarter results in webcast update
Definium Therapeutics Inc : Needham Raises Target Price to $38 From $28
THOMSON REUTERS  ·  04-30
Definium Therapeutics Inc : Needham Raises Target Price to $38 From $28

Introduction

Company Name.
Definium Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.
Issue price:
--